Collegium Pharmaceutical, Inc.Collegium Pharmaceutical, Inc.Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc.

No trades
No trades

Compare with Collegium Pharmaceutical, Inc.


Market capitalization
‪885.51 M‬USD
1.52USD
‪62.87 M‬USD
‪780.57 M‬USD
‪31.84 M‬
Beta (1Y)
0.59
Last report date
Aug 6, 2026
Report period
Q2 2026
EPS
1.92USD
Revenue
‪199.88 M‬USD
Earnings call summary

Q2 2026 saw strong ADHD portfolio growth, with JORNAY PM and AZSTARYS driving revenue gains and market share, while pain portfolio revenues were mixed due to pricing pressures. Full-year guidance was raised for AZSTARYS, and capital deployment remains disciplined.

Employees (FY)
423
Change (1Y)
+66+18.49%
Revenue / Employee (1Y)
‪1.85 M‬USD
Net income / Employee (1Y)
‪148.63 K‬USD

Details


CEO
Vikram Karnani
Headquarters
Stoughton
Founded
2002
IPO date
May 7, 2015
ISIN
US19459J1043
CUSIP
19459J104
FIGI
BBG000N7LPW4
Identifiers
ISIN US19459J1043
CFI code
ESVUFR
Collegium Pharmaceutical, Inc. is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. The firm has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Maturity dateFeb 15, 2029
Coupon2.88% (Fixed)

See all COLL bonds 

Weight0.05%
Market value‪51.35 M‬
Weight0.03%
Market value‪22.00 M‬
Weight0.03%
Market value‪10.46 M‬
Weight1.96%
Market value‪9.90 M‬
Weight0.05%
Market value‪7.86 M‬
Weight0.09%
Market value‪7.78 M‬
Weight0.05%
Market value‪7.73 M‬
Weight0.18%
Market value‪7.09 M‬
Weight0.04%
Market value‪6.86 M‬
Weight1.82%
Market value‪6.81 M‬
Weight0.19%
Market value‪6.07 M‬

Explore more ETFs 

Frequently asked questions


The current price of COLL is 25.97 USD — it has decreased by −4.49% in the past 24 hours. Watch Collegium Pharmaceutical, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Collegium Pharmaceutical, Inc. stocks are traded under the ticker COLL.
COLL stock has fallen by −26.73% compared to the previous week, the month change is a −28.07% fall, over the last year Collegium Pharmaceutical, Inc. has showed a −28.79% decrease.
We've gathered analysts' opinions on Collegium Pharmaceutical, Inc. future price: according to them, COLL price has a max estimate of 60.00 USD and a min estimate of 43.00 USD. Watch COLL chart and read a more detailed Collegium Pharmaceutical, Inc. stock forecast: see what analysts think of Collegium Pharmaceutical, Inc. and suggest that you do with its stocks.
COLL reached its all-time high on Dec 29, 2025 with the price of 50.79 USD, and its all-time low was 7.37 USD and was reached on May 9, 2017. View more price dynamics on COLL chart.
See other stocks reaching their highest and lowest prices.
COLL stock is 4.04% volatile and has beta coefficient of 0.59. Track Collegium Pharmaceutical, Inc. stock price on the chart and check out the list of the most volatile stocks — is Collegium Pharmaceutical, Inc. there?
Today Collegium Pharmaceutical, Inc. has the market capitalization of ‪845.79 M‬, it has increased by 3.40% over the last week.
Yes, you can track Collegium Pharmaceutical, Inc. financials in yearly and quarterly reports right on TradingView.
Collegium Pharmaceutical, Inc. is going to release the next earnings report on Nov 5, 2026. Keep track of upcoming events with our Earnings Calendar.
COLL earnings for the last quarter are 1.92 USD per share, whereas the estimation was 1.72 USD resulting in a 11.69% surprise. The estimated earnings for the next quarter are 1.90 USD per share. See more details about Collegium Pharmaceutical, Inc. earnings.
Collegium Pharmaceutical, Inc. revenue for the last quarter amounts to ‪199.88 M‬ USD, despite the estimated figure of ‪199.63 M‬ USD. In the next quarter, revenue is expected to reach ‪218.47 M‬ USD.
COLL net income for the last quarter is ‪−15.05 M‬ USD, while the quarter before that showed ‪14.50 M‬ USD of net income which accounts for 0.00% change. Track more Collegium Pharmaceutical, Inc. financial stats to get the full picture.
No, COLL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Aug 12, 2026, the company has 423 employees. See our rating of the largest employees — is Collegium Pharmaceutical, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Collegium Pharmaceutical, Inc. EBITDA is ‪396.20 M‬ USD, and current EBITDA margin is 52.93%. See more stats in Collegium Pharmaceutical, Inc. financial statements.
Like other stocks, COLL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Collegium Pharmaceutical, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Collegium Pharmaceutical, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Collegium Pharmaceutical, Inc. stock shows the strong sell signal. See more of Collegium Pharmaceutical, Inc. technicals for a more comprehensive analysis.